The clinical value of clinical treatment score post-5 years in patients with premenopausal breast cancer: a retrospective analysis of ASTRRA trial
Open Access
- 12 August 2026
- journal article
- Published by Elsevier in The Breast
- Vol. 89, 104900
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health and Welfare (RS-2024-00396822)
This publication has 14 references indexed in Scilit:
- Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort StudyJournal of Clinical Oncology, 2026
- Abstract PS3-07-09: Extended Endocrine Therapy (eET) Following Five Years of Adjuvant LHRH-agonist (LHRHa) in Premenopausal Patients with Node-Positive, Hormone Receptor (HR)-Positive early Breast Cancer (eBC): a subanalysis according to surrogate subtypesClinical Cancer Research, 2026
- Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studiesThe Oncologist, 2025
- Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis PredictionAmerican Journal of Clinical Oncology, 2023
- Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III TrialJournal of Clinical Oncology, 2020
- Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5Journal of Clinical Oncology, 2018
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 YearsNew England Journal of Medicine, 2017
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upThe Lancet Oncology, 2011
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialThe Lancet Oncology, 2010
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005